These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34425712)

  • 1. Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives.
    Lleo A; Gershwin ME
    Expert Rev Clin Immunol; 2021 Sep; 17(9):933-936. PubMed ID: 34425712
    [No Abstract]   [Full Text] [Related]  

  • 2. The Roadmap of RANKL/RANK Pathway in Cancer.
    Casimiro S; Vilhais G; Gomes I; Costa L
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL/RANK-beyond bones.
    Hanada R; Hanada T; Sigl V; Schramek D; Penninger JM
    J Mol Med (Berl); 2011 Jul; 89(7):647-56. PubMed ID: 21445556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [RANKL Biology ~Beyond the bone biology~].
    Nakashima T
    Clin Calcium; 2016 Aug; 26(8):1135-42. PubMed ID: 27461496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain.
    Wang K; Hackney JR; Siegal GP; Wei S
    Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
    Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
    Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer.
    van Dam PA; Verhoeven Y; Trinh XB
    Adv Exp Med Biol; 2020; 1277():53-62. PubMed ID: 33119864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
    Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
    Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL/RANK - from bone physiology to breast cancer.
    Sigl V; Penninger JM
    Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Expression of Matrix Metalloproteinases in Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-expressing Cancer of Apocrine Origin.
    Kambayashi Y; Fujimura T; Furudate S; Lyu C; Hidaka T; Kakizaki A; Sato Y; Tanita K; Aiba S
    Anticancer Res; 2018 Jan; 38(1):113-120. PubMed ID: 29277763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the G-Protein-Coupled Receptor 4 in the Increased Expression of RANK/RANKL/OPG System and Neurotrophins by Nucleus Pulposus Cells under the Degenerated Intervertebral Disc-Like Acidic Microenvironment.
    Li H; Liu H; Zhang N; Zhu Z
    Biomed Res Int; 2020; 2020():1328436. PubMed ID: 32566653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the RANKL/RANK/OPG system in the central nervous systems (CNS).
    Hanada R
    J Bone Miner Metab; 2021 Jan; 39(1):64-70. PubMed ID: 32888064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK ligand.
    Blair JM; Zheng Y; Dunstan CR
    Int J Biochem Cell Biol; 2007; 39(6):1077-81. PubMed ID: 17174136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
    van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
    Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting RANKL in breast cancer: bone metastasis and beyond.
    Azim H; Azim HA
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
    Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
    Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
    Peters S; Clézardin P; Márquez-Rodas I; Niepel D; Gedye C
    Clin Transl Oncol; 2019 Aug; 21(8):977-991. PubMed ID: 30656607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.
    Kaneko K; Kusunoki N; Hasunuma T; Kawai S
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E1909-17. PubMed ID: 22791764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.